hCD3EDG/hCD19/hBCMA
Nomenclature
C57BL/6JSmo-Tnfrsf17tm1(hBCMA)Cd3etm1(hCD3E)Cd3dtm1(hCD3D)Cd3gtm1(hCD3G)Cd19tm1(hCD19)Smoc
Cat. NO.
NM-XA-242443
Strain State
Repository Live
Model Description
Validation Data

Fig.1 Expression analysis of hBCMA in spleen of hCD3EDG/hCD19/hBCMA humanized mice.
Leukocytes were collected from homozygous hCD3EDG/hCD19/hBCMA mice that had been treated with or without GSI (γ-secretase inhibitor) in vivo, and analyzed by flow cytometry with anti-hBCMA. hBCMA was exclusively detectable in hBCMA humanized mice but not in wild-type mice.

Fig.2 Expression analysis of hBCMA in spleen of hCD3EDG/hCD19/hBCMA humanized mice.
Leukocytes were collected from homozygous hCD3EDG/hCD19/hBCMA mice, treated with or without 1 μM GSI (γ-secretase inhibitor) in vitro, and analyzed by flow cytometry with anti-hBCMA. hBCMA was exclusively detectable in hBCMA humanized mice but not in wild-type mice.

Fig.3 Detection of immune cell subpopulations in the blood of 7-8-week-old female mice by FACS (n=3 in all groups).
Abbr. WT, wild type; HO, homozygous.

Fig.4 Detection of immune cell subpopulations in the blood of 7-8-week-old male mice by FACS (n=3 in all groups).
Abbr. WT, wild type; HO, homozygous.

Fig.5 Detection of immune cell subpopulations in the spleen of 7-8-week-old female mice by FACS (n=3 in all groups).
Abbr. WT, wild type; HO, homozygous.

Fig.6 Detection of immune cell subpopulations in the spleen of 7-8-week-old male mice by FACS (n=3 in all groups).
Abbr. WT, wild type; HO, homozygous.

Fig.7 Detection of immune cell subpopulations in the lymph nodes of 7-8-week-old female mice by FACS (n=2 or 3).
Abbr. WT, wild type; HO, homozygous.

Fig.8 Detection of immune cell subpopulations in the lymph nodes of 7-8-week-old male mice by FACS (n=3 in all groups).
Abbr. WT, wild type; HO, homozygous.

Table 1. Blood routine examination of hBCMA/hCD3EDG/hCD19 knockin mice. The baseline physiological parameters of hCD3EDG/hCD19/hBCMA mice showed no significant abnormalities.
Abbr. HO, homozygous; WT, wild type. Values are expressed as mean±SEM.

Table 2. Biochemical test of serum from hBCMA/hCD3EDG/hCD19 knockin mice.
Abbr. HO, homozygous; WT, wild type. Values are expressed as mean±SEM.

Fig.9 In vivo efficacy study of teclistamab in HO hCD3EDG/hCD19/hBCMA mice. Teclistamab were injected at day 0, 3, 5, and immune cells in the spleen and bone marrow of mice after therapy were measured by flow cytometry (n=4).
Teclistamab treatment resulted in a significant reduction of plasma cells in both the spleen and bone marrow of hCD3EDG/hCD19/hBCMA mice. Average±SEM.

Fig.10 Detection of BCMA expression in serum of hTROP2 mice by ELISA.

Fig11. Homozygous hCD3EDG/hCD19/hBCMA mice express human CD3 on TACI+ CD138+ plasma cells.

Fig12. Homozygous hCD3EDG/hCD19/hBCMA mice express human CD19 on TACI+ CD138+ plasma cells.

Fig13. Homozygous hCD3EDG/hCD19/hBCMA mice express human BCMA on TACI+ CD138+ plasma cells.
You may also like
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn moreMilestones
Our vision is to provide researchers all over the world with comprehensive, convenient and professional animal model services to facilitate a simplified and highly-efficient approach towards uncovering the mysteries of life.
Learn more